ArticleCureus2026
Duloxetine-Induced Reversible Central Hypothyroidism: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central hypothyroidism (CeH) is a rare disease caused by impaired production of thyroid-stimulating hormone (TSH), usually associated with multiple pituitary hormone deficiencies. Antidepressants have been proposed as a potential cause of an isolated form of CeH, but evidence is scarce. Here, we describe a case of a 58-year-old male with isolated low free thyroxine (fT4) and inappropriately normal TSH levels, diagnosed during treatment with duloxetine. No pituitary or thyroid disease was identified, and imaging studies were unremarkable. After exclusion of alternative causes, low-dose levothyroxine (LT4) was initiated. Following the gradual discontinuation of duloxetine and LT4, thyroid function fully normalized and remained stable at follow-up. The temporal relationship and reversibility support a possible causal role of duloxetine in inducing CeH. Although the underlying mechanisms remain unclear, this case highlights the need to consider drug-induced CeH in patients receiving antidepressants. Further studies are needed to confirm this rare association and its clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.